Equillium, INC 10-Q quarterly reports

Equillium, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $5.3 million and a cash balance of $61.3 million, while advancing its EQ504 program.

Equillium, a clinical-stage biotech, reported increased net losses and a strategic pivot to its EQ504 program, bolstered by a $30 million private placement and termination of its itolizumab collaborations.

Equillium, Inc. announced a $30 million private placement and a strategic pivot to its EQ504 program, following the termination of its lead itolizumab clinical development due to unfavorable FDA feedback and trial results.

Equillium reports Q1 2025 results with a net loss of $8.7 million and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Equillium, Inc. reports Q3 2024 results, pausing development of EQ101 and EQ302 to prioritize itolizumab (EQ001) after Ono Pharmaceutical Co., Ltd. option expires.

Equillium Inc. reports a net income of $468,000 for the three months ended June 30, 2024, driven by revenue from its Asset Purchase Agreement with Ono Pharmaceutical Co., Ltd.

Equillium, Inc. announced its first quarter 2024 financial results, highlighting a revenue increase to $10.7 million driven by its partnership with Ono Pharmaceutical Co., Ltd.